tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Arrowhead Pharmaceuticals’ ARO-INHBE Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany AnnouncementsArrowhead Pharmaceuticals’ ARO-INHBE Study: A Potential Game-Changer in Obesity Treatment
2d ago
Arrowhead Pharmaceuticals’ ARO-ALK7 Study: A Potential Game-Changer in Obesity Treatment
Premium
Company Announcements
Arrowhead Pharmaceuticals’ ARO-ALK7 Study: A Potential Game-Changer in Obesity Treatment
2d ago
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia
Premium
Company Announcements
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia
2d ago
Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
PremiumMarket NewsMonte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
1M ago
Arrowhead Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Premium
Ratings
Arrowhead Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
1M ago
Arrowhead Pharmaceuticals Faces Patent Lawsuit from Ionis
Premium
Company Announcements
Arrowhead Pharmaceuticals Faces Patent Lawsuit from Ionis
2M ago
Cautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns
PremiumRatingsCautious Optimism: Hold Rating for Arrowhead Pharmaceuticals Amid Novartis Collaboration and Balance Sheet Concerns
2M ago
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
2M ago
Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis
Premium
Market News
Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100